Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEFA14A
Source: 0000886163-25-000027
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEFA14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

#### SCHEDULE 14A

#### PROXY STATEMENT PURSUANT TO SECTION 14(a) OF

#### THE SECURITIES EXCHANGE ACT OF 1934
<div align='center'>(Amendment No.___)</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |     | Definitive Proxy Statement                                                      |
| ☒ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material under 240.14a-12                                            |

### LIGAND PHARMACEUTICALS INCORPORATED

#### Name of Registrant as Specified In Its Charter
<div align='center'>Name of Person(s) Filing Proxy Statement, if other than the Registrant</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |